GlassScriptPhysician profile
Justin Donaghy
NPI 1558712992
$4,046.22
in general payments reported to CMS, 2019-2025
43 companies · $928 in 2025
The $928 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.94 · 2021: $401 · 2022: $801 · 2023: $1,023 · 2024: $879 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.33 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $382.11 | 2021-2025 | |
| Biogen, INC. | $291.56 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Lundbeck LLC | $253.70 | 2024-2025 | Vyepti |
| Sk Life Science, INC. | $250.45 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $208.58 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Harmony Biosciences LLC | $171.97 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $150.17 | 2021-2025 | |
| Celgene Corporation | $124.47 | 2022-2025 | Zeposia |
| Acadia Pharmaceuticals INC | $112.82 | 2023-2024 | Nuplazid |
| Tg Therapeutics, INC. | $110.31 | 2024-2025 | |
| Ucb, INC. | $106.97 | 2022-2023 | Briviact, Fintepla |
| Sunovion Pharmaceuticals INC. | $101.53 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $90.20 | 2024-2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $85.71 | 2022-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $85.32 | 2021-2023 | |
| Eisai INC. | $80.36 | 2021-2024 | |
| Amgen INC. | $71.63 | 2021-2023 | Aimovig |
| Csl Behring | $64.45 | 2022-2024 | Hizentra |
| Biohaven Pharmaceuticals, INC. | $62.83 | 2021 | |
| Lilly USA, LLC | $57.26 | 2024-2025 | Emgality, Kisunla, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $56.73 | 2022 | |
| Genentech USA, INC. | $54.39 | 2021-2023 | Enspryng, Ocrevus |
| Inspire Medical Systems, INC. | $53.54 | 2024-2025 | Inspire |
| Axsome Therapeutics, INC. | $48.47 | 2022-2025 | Sunosi |
| Ge Healthcare | $43.46 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $42.13 | 2022-2023 | Acthar |
| Emd Serono, INC. | $41.75 | 2022-2025 | |
| Argenx US, INC. | $40.90 | 2024 | Vyvgart Hytrulo |
| Grifols USA, LLC | $34.77 | 2024 | Gamunex-C |
| Amylyx Pharmaceuticals, INC. | $24.70 | 2023 | Relyvrio |
| Amneal Pharmaceuticals LLC | $23.77 | 2024 | Ongentys 50mg Capsules 30 |
| Medtronic, INC. | $22.82 | 2023 | Synchromedii |
| Alexion Pharmaceuticals, INC. | $22.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.81 | 2023 | |
| Mdd US Operations, LLC | $20.65 | 2022 | |
| Impel Pharmaceuticals INC. | $19.44 | 2023 | Trudhesa |
| Avion Pharmaceuticals | $18.97 | 2023 | Dhivy |
| E.R. Squibb & Sons, L.L.C. | $17.95 | 2022 | |
| Livanova USA, INC. | $17.69 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $17.67 | 2023 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $15.88 | 2023 | Nourianz |
| Zoll Respicardia, INC. | $14.56 | 2024 | Remede System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Donaghy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.